Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus BREVICON 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus BREVICON 28 DAY.
BALZIVA-28 vs BREVICON 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive